Germany’s BioNTech to buy CureVac to boost cancer research

Germany’s BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialized in mRNA technology with the goal of advancing cancer treatments.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup